Abbott Defeated In HCV Patent Spat

Law360, New York (January 4, 2007, 12:00 AM EST) -- In a blow to Abbott Laboratories, a federal judge has upheld a jury’s decision to award Belgian biotechnology company Innogenetics NV $7 million in damages in the duo’s long-standing battle over a hepatitis C virus genotyping patent.

On Thursday, Innogenetics revealed that a Wisconsin district judge had sustained the jury’s earlier verdict and damages award, hailing the decision as a victory for innovators.

"Today's ruling sends a message to companies large and small that mistakenly believe they can misappropriate others' innovations without regard for the law,"...
To view the full article, register now.